Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05389215 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting Site details revised at 30 of 30 sitesv7 Show 1 more changeShow less
    • Site details revised at 30 of 30 sites
  2. Primary completion date: Sep 1, 2025 to Oct 13, 2026 Completion date: Dec 19, 2025 to Jan 30, 2027 · Site details revised at 6 of 30 sitesv6 Show 2 more changesShow less
    • Completion date: Dec 19, 2025 to Jan 30, 2027
    • Site details revised at 6 of 30 sites
  3. Primary completion date: Jun 30, 2024 to Sep 1, 2025 Study sites: 13 to 30 · Completion date: Aug 31, 2024 to Dec 19, 2025v5 Show 2 more changesShow less
    • Study sites: 13 to 30
    • Completion date: Aug 31, 2024 to Dec 19, 2025
  4. Eligibility criteria expanded, about 79 wordsv4 See this version in full on ClinicalTrials.gov ↗
  5. Trial status: Not Yet Recruiting to Recruiting Study sites: 1 to 13 · Primary completion date: Apr 30, 2024 to Jun 30, 2024 · Completion date: May 31, 2024 to Aug 31, 2024 · 1 morev3 Show 4 more changesShow less
    • Study sites: 1 to 13
    • Primary completion date: Apr 30, 2024 to Jun 30, 2024
    • Completion date: May 31, 2024 to Aug 31, 2024
    • Start date changed from estimate of Aug 30, 2022 to Jul 29, 2022
  6. Study site revisedv2 See this version in full on ClinicalTrials.gov ↗
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.
Trial Details
NCT Number NCT05389215
Lead Sponsor Daewoong Pharmaceutical Co. LTD.
Conditions Idiopathic Pulmonary Fibrosis
Enrollment 102 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov